Filing Flows

Filing Flows › Amneal Pharmaceuticals (AMRX) › Next earnings date

Amneal Pharmaceuticals (AMRX) earnings: beat the estimate

Amneal Pharmaceuticals (AMRX) reported on Nov 3, 2026 and beat the EPS estimate: $0.26 against $0.24 (+9.5%). Revenue was $863M for Q3 2026, +10% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+9.5% vs estimate
Beat rate100%

The last report

Amneal Pharmaceuticals reported revenue of $863M for the third quarter 2026 (+10% Y/Y), net earnings $12.3M. How it makes money → · Every quarter →

Amneal Pharmaceuticals: EPS against the estimate, last 5 reportsAmneal Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.14$0.17Oct 25$0.18$0.21Feb 26$0.17$0.27May 26$0.23$0.30Jul 26$0.24$0.26Nov 26
Latest (Nov 26): Estimate $0.24, Reported $0.26.

Amneal Pharmaceuticals' latest quarter

Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Amneal Pharmaceuticals beat earnings?

Amneal Pharmaceuticals (AMRX) reported on Nov 3, 2026 and beat the EPS estimate: $0.26 against $0.24 (+9.5%).

When does AMRX report earnings?

The next date is not set yet.

Does Amneal Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.